Plexxikon is an American drug discovery company based in Berkeley, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches.
- Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders. The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.
- "Daiichi Sankyo to Acquire Plexxikon".
- News on Wyeth collaboration
- PLX204 trial
- "Fms/Trk tyrosine kinase inhibitor PLX7486". NCI Drug Dictionary. National Cancer Institute.
- Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors